Products for Research Use Only

Capecitabine-d11

CAT: 0804-HY-B0016SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0016SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Capecitabine-d11 is the deuterium labeled Capecitabine. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase[1][2].
CAS Number
1132662-08-8
UNSPSC
12352005
Hazard Statement
H341, H350, H360, H402
Target
Apoptosis; DNA/RNA Synthesis; Isotope-Labeled Compounds; Nucleoside Antimetabolite/Analog
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99
Solubility
DMSO : 250 mg/mL (ultrasonic; warming)
Smiles
C[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(C(F)=C2)NC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)=O)O1)O)O
Molecular Formula
C15H11D11FN3O6
Molecular Weight
370.42
Precautions
H341, H350, H360, H402
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27 (1) : 23-44.|[3]Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44 (2) :310-7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported